109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
关键纳米策略助力攻克顺铂耐药性，推动抗癌疗法发展
Authors Lei SY , Qin H, Liu S , Sheng J
Received 8 July 2025
Accepted for publication 22 October 2025
Published 3 November 2025 Volume 2025:20 Pages 13255—13292
DOI https://doi.org/10.2147/IJN.S551752
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Farooq A. Shiekh
Shuang-Yin Lei,1,2 Hanjiao Qin,3 Shui Liu,1 Jiyao Sheng1,4
1Department of Hepatobiliary and Pancreatic Surgery, Second Hospital of Jilin University, Changchun, 130041, People’s Republic of China; 2The First Norman Bethune Clinical College of Jilin University, Changchun, 130021, People’s Republic of China; 3Department of Radiotherapy, Second Hospital of Jilin University, Changchun, 130041, People’s Republic of China; 4State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, College of Chemistry, Jilin University, Changchun, 130012, People’s Republic of China
Correspondence: Jiyao Sheng, Email shengjiyao@jlu.edu.cn
Abstract: Cisplatin (CDDP) and other platinum-based agents remain cornerstones of cancer therapy. However, drug resistance severely impairs their clinical efficacy and therapeutic potential. Extensive research has identified diverse CDDP resistance mechanisms, broadly categorized as pre-target, on-target, off-target, and post-target resistance. These mechanisms exhibit substantial heterogeneity across patients and tumor types, highlighting the complexity of resistance development. Notably, resistance to other platinum drugs shares similarities with CDDP, presenting a common therapeutic challenge. Leveraging insights into CDDP resistance, personalized therapeutic strategies offer promise to enhance anti-tumor efficacy and overcome platinum resistance. The integration of nanotechnology and precision medicine has emerged as a pivotal frontier in oncology, where nanotechnology-based drug delivery systems (NDDSs) serve as multifunctional vectors for co-delivering CDDP and resistance-modulating agents. These intelligent platforms enable precise targeting and active circumvention of resistance mechanisms. This review comprehensively explores innovative NDDS strategies to overcome CDDP resistance, focusing on pre-target, on-target, off-target, and post-target mechanisms within a precision medicine framework. By synthesizing these advancements, we aim to provide a forward-looking perspective on NDDSs development and their potential to address the persistent challenge of platinum resistance in anti-cancer therapy.
Keywords: cisplatin, nanotechnology, drug resistance, platinum-based drugs, cancer
1Department of Hepatobiliary and Pancreatic Surgery, Second Hospital of Jilin University, Changchun, 130041, People’s Republic of China; 2The First Norman Bethune Clinical College of Jilin University, Changchun, 130021, People’s Republic of China; 3Department of Radiotherapy, Second Hospital of Jilin University, Changchun, 130041, People’s Republic of China; 4State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, College of Chemistry, Jilin University, Changchun, 130012, People’s Republic of China
Correspondence: Jiyao Sheng, Email shengjiyao@jlu.edu.cn
Abstract: Cisplatin (CDDP) and other platinum-based agents remain cornerstones of cancer therapy. However, drug resistance severely impairs their clinical efficacy and therapeutic potential. Extensive research has identified diverse CDDP resistance mechanisms, broadly categorized as pre-target, on-target, off-target, and post-target resistance. These mechanisms exhibit substantial heterogeneity across patients and tumor types, highlighting the complexity of resistance development. Notably, resistance to other platinum drugs shares similarities with CDDP, presenting a common therapeutic challenge. Leveraging insights into CDDP resistance, personalized therapeutic strategies offer promise to enhance anti-tumor efficacy and overcome platinum resistance. The integration of nanotechnology and precision medicine has emerged as a pivotal frontier in oncology, where nanotechnology-based drug delivery systems (NDDSs) serve as multifunctional vectors for co-delivering CDDP and resistance-modulating agents. These intelligent platforms enable precise targeting and active circumvention of resistance mechanisms. This review comprehensively explores innovative NDDS strategies to overcome CDDP resistance, focusing on pre-target, on-target, off-target, and post-target mechanisms within a precision medicine framework. By synthesizing these advancements, we aim to provide a forward-looking perspective on NDDSs development and their potential to address the persistent challenge of platinum resistance in anti-cancer therapy.
Keywords: cisplatin, nanotechnology, drug resistance, platinum-based drugs, cancer